Search results
Added:
3 years ago
Heart failure (HF) is a major health problem and about 6 million adults are affected in the US alone, at a cost of approximately $20 billion per year.1 Despite the availability of new treatment strategies, the incidence, number of hospitalizations and mortality associated with HF remains a big health burden.1 In addition to increasing age, the factors that contribute to poor prognosis for people…
View more
Added:
3 years ago
A patient presents to their physician with progressive dyspnea on exertion, orthopnea, and fatigue. Physical examination reveals bibasal rales, distended neck veins, an S3 gallop, and an apical holo-systolic murmur. The clinical diagnosis is straightforward - this patient has congestive heart failure.Almost certainly one of the first tests performed in this patientÔÇÖs diagnostic evaluation will…
View more
Added:
1 year ago
HFSA 22 - In this interview, Dr Juuso Blomster (Precordior Ltd, Turku, FI) joins us to share the results of the REFLECS Trial (NCT04378179), originally presented at HFSA 2022.
This trial aimed to evaluate the Precordior CardioSignal app's efficacy in measuring patients cardiac motion and function in comparison to echocardiography. Over 200 patients were recruited to this observational study.
…
View more
ACC 23: The BMAD Trial
Added:
1 year ago
Video
Added:
1 year ago
Prof John Cleland (University of Glasgow & Glasgow Royal Infirmary, Glasgow, UK) joined us to talk about heart failure management highlights in 2022 including a new phenotype, HFsnEF; available and new treatment options; news on SGLT2is and more.
Recorded at Heart Failure 2022, Madrid.
Videographer: Tom Green
Editor: Mirjam Boros
View more
Start date:
Aug 27, 2023
End date:
Aug 27, 2023
Radcliffe Medical Education present a satellite symposium entitled ‘Implementing Heart Failure Guidelines with Collaborative Care’ at the ESC Congress 2023 in Amsterdam, NL. Join us in the Riga Lecture Room, or online, on Sunday 27 August 2023, from 12:45 to 13:45 CEST.
This session, chaired by Prof Carolyn Lam (National Heart Centre Singapore, SG), provides an excellent opportunity for…
View more
Added:
3 years ago
Biomarkers have become central to the management of cardiovascular disease, and their potential clinical applications continue to grow. This article reviews galectin-3 (Gal-3), a novel biomarker of fibrosis and remodeling, and its clinical application in heart failure (HF).
Case Studies
Case Study One
A 63-year-old African-American female presents to the emergency department with acute dyspnea…
View more
Added:
11 months ago
ESC-HFA 2023 —In this discussion, late-breaker host and principal investigator of PACT-HF, Dr Harriette Van Spall(McMaster University, CA) is joined by investigators Dr Jozine ter Maaten(The University Medical Center Groningen, NL) and Dr Tariq Ahmad(Yale School of Medicine, US). The focus of their conversation revolved around the latest data on the hospital-to-home transition in heart failure,…
View more
Added:
3 years ago
The prevalence of heart failure and the resultant mortality has continued to rise despite increased understanding of the pathogenesis and improvement in management strategies.1 Left ventricular (LV) dysfunction is the final stage of most primary cardiovascular diseases, and greater severity is directly correlated with worse prognosis. The principal manifestation of heart failure progression is a…
View more
Added:
1 year ago
ESC 22 - Dr Muthiah Vaduganathan joins us on-site at ESC 2022 to discuss the findings of a prespecified meta-analysis of the EMPEROR-Preserved and DELIVER Trials, both of which aimed to evaluate the effects of SGLT2 inhibitors on patients with heart failure.
Questions:
1. What were the prespecifications for this meta-analysis?
2. What was the rationale for performing a meta-analysis on these…
View more
« First